Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Algorae Pharmaceuticals Driving Expansion with Innovation and Commercialisation
Algorae Pharmaceuticals (ASX: 1AI) has reported a period of significant expansion as it broadens its operations to include complementary commercial activities. In the three months to end September, the company advanced its dual-track strategy of AI-driven innovation and pharmaceutical commercialisation, securing two landmark deals to expand its presence across Australia and New Zealand. Algorae also advanced […]
October 29, 2025
Latest Stories
Genetic Signatures Reports Regional Success of EasyScreen Gastrointestinal Parasite Detection Kit
Genetic Signatures (ASX: GSS) has reported a strong start to the new financial year with the commercial success of its EasyScreen gastrointestinal parasite detection testing kit across all operating regions, and a 20% increase in sales for the quarter to $5.4 million. Revenue contributions came from new business with existing customers in Australia, which experienced […]
Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership
Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets. The agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration (TGA) registration to enable commercialisation of […]
TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours
TrivarX (ASX: TRI) has announced plans to acquire novel Stabl-Im metastatic brain technology and associated stable isotope cancer diagnostic intellectual property from Australian company Nucleics. Stabl-Im represents a potential breakthrough in the safe and non-invasive detection of brain cancers and metastases using standard magnetic resonance imaging (MRI) equipment to visualise and monitor tumour growth without the […]
Biotron Announces $2.5 Million Capital Raising to Fund Sedarex Acquisition
Biotron (ASX: BIT) has announced the acquisition of unlisted company Sedarex Limited, the owner of SedRx — a patented next-generation general anaesthetic — alongside a $2.5 million capital raising to fund the transaction and advance development programs. The acquisition delivers Biotron a late-stage clinical asset supported by US Food and Drug Administration (FDA) and European Medicines […]
EVE Health Secures $1.1m Funding to Propel Dyspro and Libbo Product Launches
EVE Health Group (ASX: EVE) has received stong support from sophisticated and professional investors for a capital raising aimed at accelerating the commercial rollout of its lead pharmaceutical products Dyspro and Libbo. When the placement attracted bids in excess of the $1 million EVE initially sought, the company increased the offer to $1.1m, the maximum capacity […]
Dimerix Reports Positive Data Supporting Action3 Study of DMX-200 to Treat Kidney Disease
Dimerix (ASX: DXB) has received final data analysis from the international PARASOL collaboration that reinforces support for proteinuria-based endpoints in its pivotal Phase 3 Action3 study on DMX-200 for the treatment of kidney disease. The multi-centre, randomised, double-blind, placebo-controlled study is testing the drug’s efficacy and safety in patients with focal segmental glomerulosclerosis (FSGS) who are […]
ECS Botanics Achieves Positive Cash Flow Breakthrough in September Quarter
ECS Botanics Holdings (ASX: ECS) has delivered a positive net operating cash flow of $140,000 for the three months to end September, representing an improvement of $1.6 million on the June quarter and $900,000 on the same time last year. The company’s direct-to-consumer (B2C) strategy generated strong results to complement its established business-to-business (B2B) and export […]
Race Oncology Identifies Breakthrough Anticancer Mechanism for Bisantrene (RCDS1)
Race Oncology (ASX: RAC) has discovered the primary anticancer mechanism of action for its lead drug candidate (E,E)-bisantrene, also known as RCDS1. New studies show the compound acts by binding to special DNA and RNA structures called G-quadruplexes, or G4s, which regulate many cancer-driving genes including the master switch MYC. Chief executive officer Dr Daniel Tillett […]
EVE Health Group Confirms First Australian Prescriptions of Dyspro, Launches Support Platform
EVE Health Group (ASX: EVE) has prescribed its Dyspro cannabinoid-based gummy for the treatment of dysmenorrhoea and endometriosis to Australian patients for the first time. EVE issued the drug under the Therapeutic Goods Administration’s Special Access Scheme, marking the company’s transition from production and distribution to real-world patient access. The milestone follows the company’s successful completion […]
Orthocell Appoints First Canadian Distributor For Remplir Collagen Nerve Wrap
Orthocell (ASX: OCC) has appointed the first Canadian distributor for its innovative Remplir collagen nerve wrap ahead of an official in-country launch next month. The undisclosed distributor reportedly has a wealth of expertise in the nerve, spine, and orthopaedic implant markets, with established links in the nation’s healthcare sector to drive product adoption. Orthocell has secured […]
Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset
Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers. The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an […]